Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Resistance to osimertinib is a significant challenge in treating EGFR-mutated non-small cell lung cancer (NSCLC).
• Limited data exist on the efficacy of rechallenging patients with osimertinib after initial treatment progression.
• Previous studies have explored retreatment with earlier-generation EGFR inhibitors, but not specifically osimertinib rechallenge.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of osimertinib rechallenge in EGFR-mutated NSCLC patients.
• To assess disease control and survival outcomes following osimertinib retreatment after progression on prior osimertinib and chemotherapy.
• To explore potential predictors of response to osimertinib rechallenge.

Main Methods:

• Retrospective analysis of 17 EGFR-mutated NSCLC patients rechallenged with osimertinib.
• Patients had progressed on prior osimertinib and received interim systemic therapy, including chemotherapy.
• Inclusion criteria focused on adenocarcinoma histology and specific EGFR mutations (exon 19 deletions or L858R).

Main Results:

• Osimertinib retreatment achieved a partial response in 18% and stable disease in 35% of patients, yielding a 53% disease control rate.
• Median duration of retreatment was 4.3 months, with a median overall survival of 8.9 months post-retreatment initiation.
• Some patients with central nervous system involvement experienced intracranial stability, and initial osimertinib duration did not strongly predict retreatment benefit.

Conclusions:

• Osimertinib rechallenge can offer clinically meaningful disease control in a subset of EGFR-mutated NSCLC patients.
• The oral formulation and tolerability of osimertinib make it a viable option for retreatment.
• Further research is needed to identify biomarkers for patient selection and optimize retreatment strategies, especially after interval chemotherapy.